BS69, a Specific Adaptor in the Latent Membrane Protein 1-Mediated c-Jun N-Terminal Kinase Pathway

ABSTRACT We previously demonstrated that the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) potently activates the cellular c-Jun N-terminal kinase (JNK) pathway by sequentially engaging an unknown adaptor, TRAF6, TAB1/TAK1, and JNKKs. We now show that BS69, a MYND domain-containing cellular protein, is the missing adaptor that bridges LMP1 and TRAF6, as the MYND domain and a separate region of BS69 bind to the carboxyl termini of LMP1 and TRAF6, respectively. While LMP1 promotes the interaction between BS69 and TRAF6, the complex formation between LMP1 and TRAF6 is BS69 dependent. A fraction of LMP1 and BS69 is constitutively colocalized in the membrane lipid rafts. Importantly, knockdown of BS69 by small interfering RNAs specifically inhibits JNK activation by LMP1 but not tumor necrosis factor alpha. Although overexpression of either BS69 or a mutant LMP1 without the cytoplasmic carboxyl tail is not sufficient to activate JNK, interestingly, when BS69 is covalently linked to the mutant LMP1, the chimeric protein restores the ability to activate JNK. This indicates that the recruitment and aggregation of BS69 is a prerequisite for JNK activation by LMP1.

[1]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[2]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[3]  Qian Tao,et al.  The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma , 2004, Oncogene.

[4]  G. Bishop,et al.  Requirement for TRAF3 in Signaling by LMP1 But Not CD40 in B Lymphocytes , 2004, The Journal of experimental medicine.

[5]  S. Akira,et al.  Elucidation of the c-Jun N-Terminal Kinase Pathway Mediated by Epstein-Barr Virus-Encoded Latent Membrane Protein 1 , 2004, Molecular and Cellular Biology.

[6]  E. Kieff,et al.  Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Kieff,et al.  Epstein–Barr virus latent membrane protein 1 activation of NF-κB through IRAK1 and TRAF6 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.

[9]  Shizuo Akira,et al.  Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-β (TRIF) Associates with TNF Receptor-Associated Factor 6 and TANK-Binding Kinase 1, and Activates Two Distinct Transcription Factors, NF-κB and IFN-Regulatory Factor-3, in the Toll-Like Receptor Signaling 1 , 2003, The Journal of Immunology.

[10]  Shizuo Akira,et al.  Toll-like Receptor Signaling* , 2003, Journal of Biological Chemistry.

[11]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[12]  Michael C. Ostrowski,et al.  Ets-2 interacts with co-repressor BS69 to repress target gene expression. , 2003, Anticancer research.

[13]  J. Tschopp,et al.  Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNFα-Mediated NF-κB Activation , 2003 .

[14]  Jennifer M. Martin,et al.  Transmembrane Domains 1 and 2 of the Latent Membrane Protein 1 of Epstein-Barr Virus Contain a Lipid Raft Targeting Signal and Play a Critical Role in Cytostasis , 2003, Journal of Virology.

[15]  W. Sze,et al.  Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20‐year period (1980–99): An encouraging reduction in both incidence and mortality , 2003, International journal of cancer.

[16]  L. Young,et al.  Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) Activates the Phosphatidylinositol 3-Kinase/Akt Pathway to Promote Cell Survival and Induce Actin Filament Remodeling* , 2003, The Journal of Biological Chemistry.

[17]  L. Young,et al.  TRAF1 Is a Critical Regulator of JNK Signaling by the TRAF-Binding Domain of the Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1 but Not CD40 , 2003, Journal of Virology.

[18]  K. To,et al.  Generation of monoclonal antibodies against Hong Kong nasopharyngeal carcinoma‐associated Epstein‐Barr virus latent membrane protein 1 (LMP1) , 2002, International journal of cancer.

[19]  Yu-Sun Chang,et al.  Negative Regulation of Epstein-Barr Virus Latent Membrane Protein 1-mediated Functions by the Bone Morphogenetic Protein Receptor IA-binding Protein, BRAM1* , 2002, The Journal of Biological Chemistry.

[20]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[21]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[22]  A. Leutz,et al.  The Conserved Mynd Domain of BS69 Binds Cellular and Oncoviral Proteins through a Common PXLXP Motif* , 2002, The Journal of Biological Chemistry.

[23]  Young Chul Park,et al.  All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. , 2002, Journal of cell science.

[24]  L. Young,et al.  LMP1 structure and signal transduction. , 2001, Seminars in cancer biology.

[25]  D. Thorley-Lawson,et al.  Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.

[26]  A. Kaykas,et al.  CD40 and LMP‐1 both signal from lipid rafts but LMP‐1 assembles a distinct, more efficient signaling complex , 2001, The EMBO journal.

[27]  G. Mosialos.  Cytokine signaling and Epstein-Barr virus-mediated cell transformation. , 2001, Cytokine & growth factor reviews.

[28]  E. Kieff,et al.  Epstein–Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: Protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Lipsick,et al.  BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb , 2001, Oncogene.

[30]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[31]  T. Pawson,et al.  Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.

[32]  R. Bernards,et al.  The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR , 2000, Oncogene.

[33]  E. Kieff,et al.  The Epstein-Barr Virus Oncoprotein Latent Membrane Protein 1 Engages the Tumor Necrosis Factor Receptor-Associated Proteins TRADD and Receptor-Interacting Protein (RIP) but Does Not Induce Apoptosis or Require RIP for NF-κB Activation , 1999, Molecular and Cellular Biology.

[34]  M. Karin,et al.  Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. , 1999, Genes & development.

[35]  W. Hammerschmidt,et al.  LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2 , 1999, The EMBO journal.

[36]  Hao Wu,et al.  Structural basis for self-association and receptor recognition of human TRAF2 , 1999, Nature.

[37]  L. Young,et al.  Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2 , 1999, Journal of Virology.

[38]  V. Godfrey,et al.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Young,et al.  Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) , 1998, Oncogene.

[40]  H. Shibuya,et al.  BRAM1, a BMP receptor‐associated molecule involved in BMP signalling , 1998, Genes to cells : devoted to molecular & cellular mechanisms.

[41]  M. Karin,et al.  Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase , 1997, Molecular and cellular biology.

[42]  E. Kieff,et al.  The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB , 1997 .

[43]  W. Kolch,et al.  Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.

[44]  E. Kieff,et al.  The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Tursz,et al.  High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. , 1997, Virology.

[46]  E. Kieff,et al.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Burrows,et al.  Strategies involved in developing an effective vaccine for EBV-associated diseases. , 1996, Advances in cancer research.

[48]  H. Stunnenberg,et al.  BS69, a novel adenovirus E1A‐associated protein that inhibits E1A transactivation. , 1995, The EMBO journal.

[49]  B. Sugden,et al.  Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus , 1995, Journal of virology.

[50]  M. Rowe,et al.  The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. , 1995, Oncogene.

[51]  E. Kieff,et al.  The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues , 1995, Journal of virology.

[52]  J. Schlessinger,et al.  Regulation of signal transduction and signal diversity by receptor oligomerization. , 1994, Trends in biochemical sciences.

[53]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[55]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[56]  A. Levine,et al.  Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6 , 1990, Cell.

[57]  G. Klein,et al.  Morphological transformation of human keratinocytes expressing the LMP gene of Epstein Barr virus , 1990, Nature.

[58]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[59]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.